The Danish biotech firm Genmab has lost a potential blockbuster drug. Genmab has decided to ditch the drug candidate enapotamab vedotin for treating cancer, which the firm announces in a statement.
"We are committed to developing innovative antibody products for patients with cancer, however the data from the enapotamab vedotin expansion cohorts unfortunately does not support moving this product candidate forward," states CEO Jan van de Winkel in the press announcement.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Production Director 
(Senior) Drug Substance Specialist 
Nordic Medical Affairs Manager 
Senior Project Manager (GMP - Life Science) 
Innovation Project Manager, Display Unit 
Clinical Trial Administrator 
Analytical Coordinator for Analytical Development 
Account Manager 
Communications Consultant 
Clinical Trial Manager 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Senior Chemical Safety Advisor 
Director for innovative pre-clinical testing unit 
Scientific Writer 
Senior IT Network Engineer 
System Sales Development Consultant - Investment Projects, Merck Millipore 
IRT Manager, Clinical Drug Supply 
Client Talent Acquisition Specialist 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office